Samsara Bio Capital, LLC Graphite Bio, Inc. Transaction History

Samsara Bio Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.85 - $3.21 $15.6 Million - $27.2 Million	8,459,314 New	8,459,314 $20.7 Million
Q2 2022 Aug 15, 2022	BUY	$2.14 - $5.23 $827,561 - $2.02 Million	386,711 Added 4.79%	8,459,314 $23.3 Million
Q1 2022 May 16, 2022	BUY	$5.1 - $13.06 $1.13 Million - $2.88 Million	220,670 Added 2.81%	8,072,603 $41.2 Million
Q4 2021 Feb 14, 2022	BUY	$8.41 - $16.71 $3.53 Million - $7.02 Million	420,310 Added 5.66%	7,851,933 $97.6 Million
Q2 2021 Aug 17, 2021	BUY	$18.5 - $30.73 $137 Million - $228 Million	7,431,623 New	7,431,623 $228 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.